Philippe JEAN-PIERRE

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 12/06/2023
• Auteurs : Charles JaverliatPierre RaimbaudPierre-Philippe ElstEliott ZimmermannSophie VillenaveMartin GuesneyMylène PardoenPatrick BaertGuillaume Lavoué
• Organismes : Origami Origami Origami Origami Origami Maison des Sciences de l’Homme Lyon Saint-Etienne Maison des Sciences de l’Homme Lyon Saint-Etienne Origami Origami

---

Résumé : This paper presents the concept of multisensory digital twins, a brief state of the art of existing techniques for both capturing and immersive rendering of multisensory stimuli, and a case study of multisensory digital twin creation for cultural heritage.

---

Fichiers liés : SensoryX2023.pdf

---

Source

---

• Type de publi. :
• Date de publi. : 12/06/2023
• Auteurs : Jean-Philippe Derosier
• Organismes : Centre de recherche Droits et perspectives du droit - ULR 4487

---

Résumé : La rumeur est de plus en plus intense : les jours d’Élisabeth Borne à Matignon sont comptés. Elle est surtout de plus en plus diversifiée… On a entendu les noms de Gérard Larcher, Julien Denormandie, François Baroin, Jean-Pierre Raffarin, Christine Lagarde et on en oublie certainement. Cette diversité confirme surtout qu’il ne s’agit là que de rumeurs, davantage destinées à entretenir les pulsions médiatiques qu’un objectif politique.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 09/06/2023
• Auteurs : Marine FidelleConrad RauberCarolina Alves Costa SilvaAi-Ling TianImran LahmarAnne-Laure Mallard de la VarendeLiwei ZhaoCassandra ThelemaqueIsabelle LebharMeriem MessaoudeneEugenie PizzatoRoxanne BirebentMaxime Descartes Mbogning FonkouSilvia ZoppiAnna ReniCécile DalbanMarion LeducGladys FerrereSylvère DurandPierre LyAymeric SilvinKevin MulderCharles-Antoine DutertreFlorent GinhouxSatoru YonekuraMaria Paula RobertiMaryam Tidjani AlouSafae TerrisseJianzhou ChenOliver KeppAngela SchippersNorbert WagnerJavier Suárez-GosálvezSebastian KoboldJean-Eudes FahrnerCorentin RichardJacques BosqLeonardo LordelloGiacomo VitaliNathalie GalleronBenoît QuinquisEmmanuelle Le ChatelierLucas BlanchardJean-Philippe GirardAnne JarryNadine GervoisEmmanuelle GodefroyNathalie LabarrièreRonald KoschnyRomain DaillèreBenjamin BesseCaroline TruntzerFrançois GhiringhelliNicolas CoatnoanVanessa MhannaDavid KlatzmannDamien DrubayLaurence AlbigesAndrew Maltez ThomasNicola SegataFrançois-Xavier DanlosAurélien MarabelleBertrand RoutyLisa DerosaGuido KroemerLaurence Zitvogel
• Organismes : Institut Gustave Roussy Université Paris-Saclay Immunologie anti-tumorale et immunothérapie des cancers Institut Gustave Roussy Université Paris-Saclay Heidelberg University Hospital [Heidelberg] Immunologie anti-tumorale et immunothérapie des cancers Institut Gustave Roussy Université Paris-Saclay Immunologie anti-tumorale et immunothérapie des cancers Institut Gustave Roussy Institut Gustave Roussy Immunologie anti-tumorale et immunothérapie des cancers Institut Gustave Roussy Immunologie anti-tumorale et immunothérapie des cancers Institut Gustave Roussy Centre de Recherche des Cordeliers Institut Gustave Roussy Immunologie anti-tumorale et immunothérapie des cancers Institut Gustave Roussy Immunologie anti-tumorale et immunothérapie des cancers Centre de Recherche du Centre Hospitalier de l’Université de Montréal Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Centre Léon Bérard [Lyon] Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Institut Gustave Roussy Universitätsklinikum RWTH Aachen - University Hospital Aachen [Aachen, Germany] Universitätsklinikum RWTH Aachen - University Hospital Aachen [Aachen, Germany] Klinikum der Universitat Munchen Klinikum der Universitat Munchen Institut Gustave Roussy Centre de Recherche du Centre Hospitalier de l’Université de Montréal JBO Consultant [Paris] Institut Gustave Roussy Université Paris-Saclay Université Paris-Saclay Université Paris-Saclay Université Paris-Saclay Institut de pharmacologie et de biologie structurale Institut de pharmacologie et de biologie structurale Immunology and New Concepts in ImmunoTherapy Immunology and New Concepts in ImmunoTherapy Immunology and New Concepts in ImmunoTherapy Immunology and New Concepts in ImmunoTherapy Heidelberg University Hospital [Heidelberg] Institut Gustave Roussy Institut Gustave Roussy Université de Franche-Comté Université de Franche-Comté CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Institut Gustave Roussy Institut Gustave Roussy Università degli Studi di Trento = University of Trento Università degli Studi di Trento = University of Trento Institut Gustave Roussy Immunologie anti-tumorale et immunothérapie des cancers Institut Gustave Roussy Immunologie anti-tumorale et immunothérapie des cancers Centre de Recherche du Centre Hospitalier de l’Université de Montréal Institut Gustave Roussy Sorbonne Université Centre de Recherche des Cordeliers Institut Gustave Roussy Immunologie anti-tumorale et immunothérapie des cancers
• Publié dans Science le 22/10/2020

---

Résumé : Antibiotics (ABX) compromise the efficacy of programmed cell death protein 1 (PD-1) blockade in cancer patients, but the mechanisms underlying their immunosuppressive effects remain unknown. By inducing the down-regulation of mucosal addressin cell adhesion molecule 1 (MAdCAM-1) in the ileum, post-ABX gut recolonization by Enterocloster species drove the emigration of enterotropic α4β7 + CD4 + regulatory T 17 cells into the tumor. These deleterious ABX effects were mimicked by oral gavage of Enterocloster species, by genetic deficiency, or by antibody-mediated neutralization of MAdCAM-1 and its receptor, α4β7 integrin. By contrast, fecal microbiota transplantation or interleukin-17A neutralization prevented ABX-induced immunosuppression. In independent lung, kidney, and bladder cancer patient cohorts, low serum levels of soluble MAdCAM-1 had a negative prognostic impact. Thus, the MAdCAM-1–α4β7 axis constitutes an actionable gut immune checkpoint in cancer immunosurveillance.

---

Fichiers liés : 2023_Drubay_Science.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 08/06/2023
• Auteurs : Piyu KeZhu DengBiqing ZhuBo ZhengYilong WangOlivier BoucherSimon Ben ArousChuanlong ZhouRobbie AndrewXinyu DouTaochun SunXuanren SongZhao LiFeifan YanDuo CuiYifan HuDa HuoJean-Pierre ChangRichard EngelenSteven UittenbogaartPhilippe CiaisZhu Liu
• Organismes : Institut Pierre-Simon-Laplace Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette]
• Publié dans Scientific Data le 29/10/2020

---

Résumé : With the urgent need to implement the EU countries pledges and to monitor the effectiveness of Green Deal plan, Monitoring Reporting and Verification tools are needed to track how emissions are changing for all the sectors. Current official inventories only provide annual estimates of national CO 2 emissions with a lag of 1+ year which do not capture the variations of emissions due to recent shocks including COVID lockdowns and economic rebounds, war in Ukraine. Here we present a near-real-time countrylevel dataset of daily fossil fuel and cement emissions from January 2019 through December 2021 for 27 EU countries and UK, which called Carbon Monitor Europe. The data are calculated separately for six sectors: power, industry, ground transportation, domestic aviation, international aviation and residential. Daily CO 2 emissions are estimated from a large set of activity data compiled from different sources. The goal of this dataset is to improve the timeliness and temporal resolution of emissions for European countries, to inform the public and decision makers about current emissions changes in Europe.

---

Fichiers liés : s41597-023-02284-y.pdf

---

Source

---

• Type de publi. : Pré-publication, Document de travail
• Date de publi. : 06/06/2023
• Auteurs : Florence AderNathan Peiffer-SmadjaJulien PoissyMaude Bouscambert-DuchampDrifa BelhadiAlpha DialloChristelle DelmasJuliette SaillardAline DechanetNoémie MercierAxelle DupontToni AlfaiateFrançois-Xavier LescureFrançois RaffiFrançois GoehringerAntoine KimmounStéphane JaureguiberryJean ReignierSaad NseirFrançois DanionRaphaël Clere-JehlKevin BouillerJean-Christophe NavellouViolaine TolsmaAndré CabieClément DubostJohan CourjonSylvie LeroyJoy MootienRostane GaciBruno MourvillierEmmanuel FaureValérie PourcherSébastien GallienOdile LaunayKarine LacombeJ.P. LanoixAlain MakinsonGuillaume Martin-BlondelLila BouadmaElisabeth Botelho-NeversAmandine Gagneux-BrunonOlivier EpaulardLionel PirothFlorent WalletJean-Christophe RichardJean ReuterThérèse StaubMaya HitesMarion NoretClaire AndréjakGilles PeytavinBruno LinaDominique CostagliolaYazdan YazdanpanahCharles BurdetFrance Mentre
• Organismes : Service des Maladies Infectieuses et Tropicales [Lyon] Centre International de Recherche en Infectiologie Infection, Anti-microbiens, Modélisation, Evolution Services de Maladies Infectieuses et Tropicales [CHU Bichat] Imperial College London Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 Centre Hospitalier Régional Universitaire [CHU Lille] Centre International de Recherche en Infectiologie Hospices Civils de Lyon Virology and human respiratory Pathologies - Virology and human respiratory Pathologies [CIRI] Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] ANRS - Maladies infectieuses émergentes Institut de Santé Publique Institut de Santé Publique Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique AP-HP - Hôpital Bichat - Claude Bernard [Paris] ANRS France Recherche Nord & sud Sida-hiv hépatites Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique AP-HP - Hôpital Bichat - Claude Bernard [Paris] Département d'Epidemiologie, Biostatistique et Recherche Clinique Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique AP-HP - Hôpital Bichat - Claude Bernard [Paris] Département d'Epidemiologie, Biostatistique et Recherche Clinique Infection, Anti-microbiens, Modélisation, Evolution Services de Maladies Infectieuses et Tropicales [CHU Bichat] Service des maladies infectieuses et tropicales [CHU Nantes] Service des Maladies Infectieuses et Tropicales [CHRU Nancy] Défaillance Cardiovasculaire Aiguë et Chronique Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] Service de Réanimation Médicale [CHRU Nancy] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 Hôpitaux Universitaires de Strasbourg Nouvel Hôpital Civil de Strasbourg Immuno-Rhumatologie Moléculaire Laboratoire d'excellence (Labex) Transplantex (Nouveaux loci d’histocompatibilité et biomarqueurs en transplantation humaine, de la découverte à l’application clinique) Fédération de Médecine Translationnelle de Strasbourg Centre Hospitalier Régional Universitaire de Besançon Laboratoire Chrono-environnement (UMR 6249) Centre Hospitalier Régional Universitaire de Besançon Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois] Université des Antilles Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Hôpital d'Instruction des Armées Begin [Saint-Mandé, France] CB - Centre Borelli - UMR 9010 Centre Hospitalier Universitaire de Nice Centre méditerranéen de médecine moléculaire FHU OncoAge - Pathologies liées à l’âge [CHU Nice] Centre Hospitalier Universitaire de Nice Institut de pharmacologie moléculaire et cellulaire Groupe hospitalier de la région de Mulhouse et Sud-Alsace Centre hospitalier régional de Metz-Thionville Hôpital universitaire Robert Debré [Reims] Université de Reims Champagne-Ardenne Université de Lille Centre Hospitalier Régional Universitaire [CHU Lille] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] CHU Henri Mondor [Créteil] Université Paris-Est Créteil Val-de-Marne - Paris 12 CIC Cochin Pasteur Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] CHU Amiens-Picardie Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 Département Maladies Infectieuses et Tropicales [CHRU Montpellier] CIC Montpellier Service Maladies infectieuses et tropicales [CHU Toulouse] Centre de Physiopathologie Toulouse Purpan Infection, Anti-microbiens, Modélisation, Evolution Services de Maladies Infectieuses et Tropicales [CHU Bichat] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Groupe Immunité des Muqueuses et Agents Pathogènes Centre d'Investigation Clinique - Epidémiologie Clinique [CHU Saint-Etienne] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Groupe Immunité des Muqueuses et Agents Pathogènes Centre d'Investigation Clinique - Epidémiologie Clinique [CHU Saint-Etienne] Centre Hospitalier Universitaire [CHU Grenoble] Université Grenoble Alpes Service de Maladies Infectieuses et Tropicales [CHU Dijon] Lipides - Nutrition - Cancer [Dijon - U1231] Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer Hospices Civils de Lyon Hôpital de la Croix-Rousse [CHU - HCL] Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Centre Hospitalier de Luxembourg [Luxembourg] Centre Hospitalier de Luxembourg [Luxembourg] Hôpital Erasme = Erasmus Hospital = Erasmus Ziekenhuis Réseau national de recherche clinique en infectiologie CHU Amiens-Picardie Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 Infection, Anti-microbiens, Modélisation, Evolution CIC Hôpital Bichat Centre International de Recherche en Infectiologie Virology and human respiratory Pathologies - Virology and human respiratory Pathologies [CIRI] Hospices Civils de Lyon Institut Pierre Louis d'Epidémiologie et de Santé Publique Infection, Anti-microbiens, Modélisation, Evolution Services de Maladies Infectieuses et Tropicales [CHU Bichat] Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris]

---

Résumé : Background Lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a and hydroxychloroquine efficacy for COVID-19 have been evaluated, but detailed evaluation is lacking. Objective To determine the efficacy of lopinavir/ritonavir, lopinavir/ritonavir-IFN-β-1a, hydroxychloroquine or remdesivir for improving the clinical, virological outcomes in COVID-19 inpatients. Design Open-label, randomized, adaptive, controlled trial. Setting Multi-center trial with patients from France. Participants 583 COVID-19 inpatients requiring oxygen and/or ventilatory support Intervention Standard of care (SoC, control), SoC plus lopinavir/ritonavir (400 mg lopinavir and 100 mg ritonavir every 12h for 14 days), SoC plus lopinavir/ritonavir plus IFN-ß-1a (44 μg of subcutaneous IFN-ß-1a on days 1, 3, and 6), SoC plus hydroxychloroquine (400 mg twice on day 1 then 400 mg once daily for 9 days) or SoC plus remdesivir (200 mg intravenously on day 1 then 100 mg once-daily for hospitalization duration or 10 days). Measurements The primary outcome was the clinical status at day 15, measured by the WHO 7-point ordinal scale. Secondary outcomes included SARS-CoV-2 quantification in respiratory specimens and safety analyses. Results Adjusted Odds Ratio (aOR) for the WHO 7-point ordinal scale were not in favor of investigational treatments: lopinavir/ritonavir versus control, aOR 0.83, 95%CI, 0.55 to 1.26, P=0.39; lopinavir/ritonavir-IFN-β-1a versus control, aOR 0.69, 95%CI, 0.45 to 1.04, P=0.08; hydroxychloroquine versus control, aOR 0.93, 95%CI, 0.62 to 1.41, P=0.75. No significant effect on SARS-CoV-2 RNA clearance in respiratory tract was evidenced. Lopinavir/ritonavir-containing treatments were significantly associated with more SAE. Limitations Not a placebo-controlled, no anti-inflammatory agents tested. Conclusion No improvement of the clinical status at day 15 nor SARS-CoV-2 RNA clearance in respiratory tract specimens by studied drugs. This comforts the recent Solidarity findings. Registration NCT04315948. Funding PHRC 2020, Dim OneHealth, REACTing

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 05/06/2023
• Auteurs : Pierre-André MaitreJulie CrenSylvie ValinEtienne GoudalEtienne PhilippeJean Philippe Faure
• Organismes : Département Thermique Conversion et Hydrogène Département Thermique Conversion et Hydrogène Département Thermique Conversion et Hydrogène Gaz Réseau Distribution France Gaz Réseau Distribution France Aliapur

---

Résumé : A new potential industrial pathway to valorise rubber from worn tyres into synthetic methane is assessed via a techno-economic and environmental analysis. In this process, tyre crumb is firstly gasified in an Entrained Flow Reactor (EFR), which produces syngas that is further adjusted to a H$_2$/CO ratio of 3, cleaned and finally reacted in a methanation reactor to produce synthetic methane. An industrial-scale gasifier (2.5 t/h) was modelled and all other elementary steps of the plant scaled accordingly. Two different pathways were considered: the first one, whereby the syngas adjustment is conducted by a Water Gas Shift (WGS) reactor, and a second one in which H$_2$ produced by an electrolyser is added to the gas stream. Both pathways were shown to have a similar global energy yield, whilst the electrified process demonstrated a significant improvement of carbon use (89 % vs. 35 %). The specific CO$_2$ content of the synthetic methane reached 400 kg/MWh$_{LHV}$ and 227 kg/MWh$_{LHV}$ for the pathway with WGS and the electrolyser, respectively. Finally the Levelised Cost Of methane (LCO$_{CH4}$) was estimated to be equal to 105 €/MWh synthetic fuel, waste valorisation, electrolysis, carbon assessment for the pathway with WGS and 18€/MWh$_{HHV}$ for the pathway with the electrolyser.

---

Fichiers liés : CEA_Tech-Eco-tyre_crumb_gasification.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 05/06/2023
• Auteurs : Pierre-François PerroudAnouchka Guyon-DebastJosep M CasacubertaWyatt PaulJean-Philippe PichonDavid ComeauFabien Nogué
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Centre for Research in Agricultural Genomics CSIC-IRTA-UAB-UB Groupe Limagrain BIOGEMMA Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans Journal of Experimental Botany le 25/10/2020

---

Résumé : Efficient and precise gene editing is the gold standard of any reverse genetic study. The recently developed prime editing approach, a modified CRISPR/Cas9 [clustered regularly interspaced palindromic repeats (CRISPR)/CRISPRassociated protein] editing method, has reached the precision goal but its editing rate can be improved. We present an improved methodology that allows for routine prime editing in the model plant Physcomitrium patens, whilst exploring potential new prime editing improvements. Using a standardized protoplast transfection procedure, multiple prime editing guide RNA (pegRNA) structural and prime editor variants were evaluated targeting the APT reporter gene through direct plant selection. Together, enhancements of expression of the prime editor, modifications of the 3ʹ extension of the pegRNA, and the addition of synonymous mutation in the reverse transcriptase template sequence of the pegRNA dramatically improve the editing rate without affecting the quality of the edits. Furthermore, we show that prime editing is amenable to edit a gene of interest through indirect selection, as demonstrated by the generation of a Ppdek10 mutant. Additionally, we determine that a plant retrotransposon reverse transcriptase enables prime editing. Finally, we show for the first time the possibility of performing prime editing with two independently coded peptides.

---

Fichiers liés : Perroud_et_al. 2023.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 05/06/2023
• Auteurs : Raphaël GarinPierre-Jean BouvetPhilippe ForjonelBeatrice Tomasi
• Organismes : Systèmes Embarqués, Acoustique et Télécommunications Systèmes Embarqués, Acoustique et Télécommunications Systèmes Embarqués, Acoustique et Télécommunications Norwegian Research Center

---

Résumé : Autonomous underwater vehicles localization is a challenging task due to the harsh environment of the underwater propagation channel. To reach accurate positioning, it is often required to use either a complex architecture or costly sensors. In this paper we provide the experimental results of a cost-effective technique combining underwater acoustic communication and localization through Doppler shift estimation that provides information on receiver relative speed. We consider a fixed anchor with known position transmitting regularly to a moving boat in water at a constant depth of 2 meters in a range up to 800 meters. Using an Extended Kalman filter, we compare standalone range measurements estimation with speed and range combined in the estimation filter. Experimental results demonstrate a consequent gain using speed computation associated with range measurement and a good accuracy on positioning results.

---

Fichiers liés : 2023101704-1.pdf

---

Source

---

• Type de publi. :
• Date de publi. : 05/06/2023
• Auteurs : Maha KooliHenri-Pierre CharlesThaddée BricoutJean-Philippe NoelMaria Ramirez-CorralesBastien Giraud
• Organismes : Laboratoire Fonctions Innovantes pour circuits Mixtes Laboratoire Fonctions Innovantes pour circuits Mixtes Laboratoire Fonctions Innovantes pour circuits Mixtes Laboratoire Fonctions Innovantes pour circuits Mixtes Laboratoire Fonctions Innovantes pour circuits Mixtes Laboratoire Fonctions Innovantes pour circuits Mixtes

---

Résumé : Computational SRAM (C-SRAM) is a new computing solution for Near-Memory Computing. It allows to perform operations inside or next to the memory without transferring data over the system bus, leading to significantly reducing energy consuption. Operations are realized on large vectors of data occupying the entire physical row of C-SRAM array, leading to high performance gains. This paper presents the C-SRAM solution as an integrated vector-processing unit to be used by a RISC-V processor as an energy-efficient and high performing co-processor. The proposed programming model of the C-SRAM is based on the system bus of a RISC-V processor.

---

Fichiers liés : Kooli82.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 04/06/2023
• Auteurs : Pierre DevelterJonathan BosseOlivier RabastePhilippe ForsterJean-Philippe Ovarlez
• Organismes : DEMR, ONERA, Université Paris Saclay [Palaiseau] Sondra, CentraleSupélec, Université Paris-Saclay DEMR, ONERA, Université Paris Saclay [Palaiseau] DEMR, ONERA, Université Paris Saclay [Palaiseau] Systèmes et Applications des Technologies de l'Information et de l'Energie DEMR, ONERA, Université Paris Saclay [Palaiseau] Sondra, CentraleSupélec, Université Paris-Saclay

---

Résumé : In the state-of-the-art, the Probability of False Alarm (P F A)threshold relationship for the popular Matched Filter (MF) is often derived assuming that unknown non-linear parameters lie on a grid. However, these parameters vary continuously in practice. This is known as the off-grid case. In this article, an asymptotic P F A-threshold relationship for the popular Matched Filter is derived in the off-grid case under complex white Gaussian noise hypothesis using expected Euler characteristics. This asymptotic relationship fits very well with corresponding Monte-Carlo trials in the moderate to low P F A regime.

---

Fichiers liés : ICASSP2023.pdf

---

Source